-
Repros Therapeutics Shares Rally Following Ladenburg Upgrade To Buy, Positive Data
Wednesday, November 16, 2016 - 11:43am | 299Read More...Shares of Repros Therapeutics Inc (NASDAQ: RPRX) climbed more than 8 percent in Wednesday’s pre-market hours after positive clinical data of Proellex led Ladenburg Thalmann to upgrade shares to Buy, with a $5.50 price target. Repros announced positive Phase 2b data for both its oral and...
-
Ladenburg Thalmann Positive On TG Therapeutics Post Adjustments To GENUINE Study
Friday, October 14, 2016 - 11:17am | 311Read More...Ladenburg Thalmann reaffirmed its Buy rating and raised its target price by $2 to $28 on TG Therapeutics Inc (NASDAQ: TGTX) shares following its amendment to its cancer study, GENUINE. Under GENUINE, TG Therapeutics is studying Ublituximab in combination with Ibrutinib versus Ibrutinib alone in...
-
Ladenburg Thalmann Downgrades Zosano Pharma To Neutral On Financing Overhang, Market Uncertainty
Thursday, August 11, 2016 - 8:02am | 303Read More...Ladenburg Thalmann downgraded Zosano Pharma Corp (NASDAQ: ZSAN) to Neutral from Buy as it prefers to remain on the sideline until the company improves its financial position and there is clarity of market opportunity for migraine treatment ZP-Triptan (now called M207). Zosano ended second...
